Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2

Sponsor Class

INDUSTRY 3OTHER_GOV 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 66Neoplasms 49Stomach Neoplasms 45Colorectal Neoplasms 42Carcinoma, Non-Small-Cell Lung 37Lung Neoplasms 30Uterine Cervical Neoplasms 28Rectal Neoplasms 28Carcinoma, Hepatocellular 25Prostatic Neoplasms 24Recurrence 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Ovarian Neoplasms 18Neoplasm Metastasis 16Colonic Neoplasms 16Esophageal Neoplasms 15Urinary Bladder Neoplasms 14Thyroid Neoplasms 14Pancreatic Neoplasms 14Nasopharyngeal Carcinoma 14Leukemia, Myeloid, Acute 13Head and Neck Neoplasms 13Small Cell Lung Carcinoma 11Papillomavirus Infections 11Multiple Myeloma 11Motor Activity 11Melanoma 11Lymphoma 11Sarcoma 10Lymphoma, Non-Hodgkin 10

Interventions

pyrotinib 1Drug Therapy 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × OTHER_GOV × HER2 Positive Metastatic Breast Cancer × Clear all
NCT03691051 2023-09-25

A Study of Pyrotinib Plus Capecitabine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer

Henan Cancer Hospital

Phase 2 Unknown
78 enrolled
Breast

HER2 Positive Metastatic Breast Cancer

NCT04681287 2023-09-25

Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone.

Henan Cancer Hospital

Phase 2 Unknown
46 enrolled
Breast

HER2 Positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡